Clearside Biomedical Inc (CLSDQ)

Currency in USD
0.249
-0.001(-0.40%)
Closed·
Showing Clearside Biomedical historical data. For real-time data please try another search
Fair Value
Day's Range
0.2490.249
52 wk Range
0.01013.050
Key Statistics
Prev. Close
0.249
Open
0.249
Day's Range
0.249-0.249
52 wk Range
0.01-13.05
Volume
133
Average Volume (3m)
11.6K
1-Year Change
-97.9937%
Book Value / Share
-10.31
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CLSDQ Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.000
Downside
-100.00%
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Clearside Biomedical Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 0.000

Clearside Biomedical Inc SWOT Analysis


AMD Market Disrupto
Clearside Biomedical's CLS-AX aims to revolutionize wet AMD treatment with flexible dosing, potentially addressing a significant unmet need in ophthalmology
Financial Crossroads
With $20M in cash, Clearside faces funding challenges for pivotal trials. Analyst price targets range from $4 to $8, suggesting significant upside potential
Innovative Pipeline
Explore CLS-AX's unique product profile, which could allow for personalized treatment regimens and extended dosing intervals beyond the current six-month standard
Competitive Landscape
Delve into Clearside's position in the lucrative AMD market, where its 91.05% gross profit margin and differentiated approach could provide a competitive edge
Read full SWOT analysis

Clearside Biomedical Inc Earnings Call Summary for Q4/2024

  • Q4 2024 revenue of $306,000 beat forecast of $130,140; EPS met expectations at -0.1
  • Stock fell 1.94% after-hours despite revenue beat; analysts maintain "Strong Buy" recommendation
  • Successful Phase 2b trial for CLSAX; Phase III aligned with FDA, planned for H2 2025
  • Company actively seeking funding for Phase III trials, estimated at $55-60 million per study
  • $20 million cash on hand as of Dec 31, 2024; financing remains a key challenge for future operations
Last Updated: 27/03/2025, 22:34
Read Full Transcript

Earnings

Latest Release
Nov 14, 2025
EPS / Forecast
-1.14 / -0.07
Revenue / Forecast
201K / 170K
EPS Revisions
Last 90 days

CLSDQ Income Statement

Compare CLSDQ to Peers and Sector

Metrics to compare
CLSDQ
Peers
Sector
Relationship
P/E Ratio
−0.7x−4.4x−0.3x
PEG Ratio
0.000.000.00
Price/Book
−0.3x2.7x2.6x
Price / LTM Sales
5.4x5.1x3.1x
Upside (Analyst Target)
-49.8%48.3%
Fair Value Upside
Unlock−3.2%6.7%Unlock
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.